| P50 | author | Raewyn J Hopkins | Q63658732 |
| | Robert Young | Q124161902 |
| P2860 | cites work | Clinical applications of gene-based risk prediction for lung cancer and the central role of chronic obstructive pulmonary disease | Q36320998 |
| | Association of radiographic emphysema and airflow obstruction with lung cancer | Q36915507 |
| | Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes | Q36955879 |
| | Targeting of low-dose CT screening according to the risk of lung-cancer death | Q37198867 |
| | Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study | Q37214361 |
| | Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial | Q38601785 |
| | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 |
| | The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention | Q38694004 |
| | Obstacles to and Solutions for a Successful Lung Cancer Screening Program | Q38978989 |
| | Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System. | Q39842455 |
| | Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. | Q39955550 |
| | Lung Cancer Screening in Individuals with Chronic Obstructive Pulmonary Disease. Finding the Sweet Spot. | Q40375169 |
| | Why cancer screening has never been shown to "save lives"--and what we can do about it. | Q40994873 |
| | Measures of outcome in lung cancer screening: maximising the benefits. | Q42369335 |
| | Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis | Q44293317 |
| | Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers. | Q45279047 |
| | Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort | Q46176156 |
| | Competing causes of death: a death certificate study. | Q50924609 |
| | Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? | Q51708631 |
| | Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. | Q51898509 |
| | Estimating overdiagnosis of lung cancer. | Q53113021 |
| | When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. | Q53146856 |
| | Lung cancer screening with low-dose CT (LDCT), or when a public health intervention is beyond the patient’s benefit | Q57599565 |
| | Incremental Value of Pulmonary Function and Sputum DNA Image Cytometry in Lung Cancer Risk Prediction | Q57895945 |
| | Incorporating genomic data into multivariate risk models for lung cancer | Q87194453 |
| | CT screening in COPD: impact on lung cancer mortality: de Torres JP, Casanova C, Marin JM et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir med 2013; 107: 702- | Q87549624 |
| | Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement | Q89099836 |
| | Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis | Q24815588 |
| | Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement | Q27021984 |
| | Reduced lung-cancer mortality with low-dose computed tomographic screening | Q28241954 |
| | Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation | Q28295538 |
| | Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study | Q30504247 |
| | Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up | Q30806378 |
| | Improving selection criteria for lung cancer screening. The potential role of emphysema. | Q33735712 |
| | Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care | Q33794627 |
| | Variations in lung cancer risk among smokers. | Q34184504 |
| | Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis | Q34205329 |
| | Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study | Q34315274 |
| | Baseline characteristics of participants in the randomized national lung screening trial | Q34366877 |
| | All-cause mortality in randomized trials of cancer screening | Q34520822 |
| | COPD prevalence is increased in lung cancer, independent of age, sex and smoking history | Q34604212 |
| | Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts | Q34611247 |
| | Quantitative relationships between cigarette smoking and ventilatory function | Q34730271 |
| | Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study | Q35018447 |
| | Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. | Q35090585 |
| | COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma | Q35536873 |
| | Gains in life expectancy after elimination of major causes of death: revised estimates taking into account the effect of competing causes | Q35558551 |
| | Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer | Q35897669 |
| | Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy | Q36272396 |
| P433 | issue | 3 | |
| P921 | main subject | lung cancer | Q47912 |
| | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 347-360 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Translational lung cancer research | Q26842616 |
| P1476 | title | Chronic obstructive pulmonary disease (COPD) and lung cancer screening | |
| P478 | volume | 7 | |